<DOC>
	<DOCNO>NCT02110654</DOCNO>
	<brief_summary>1. objective . To compare efficacy safety mometasone furoate nasal spray ( MFNS ; Nasonex 200μg , daily ) alone versus combination montelukast ( singulair 10mg , daily ) chronic rhinosinusitis ( CRS ) asthma functional endoscopic sinus surgery ( FESS ) improvement clinical control CRS 2. clinical hypothesis . The investigator hypothesize postoperative combine montelukast MFNS good improve clinical control CRS concomitant asthma FESS compare MFNS alone . 3. study design This study 9-month randomize , open-label , control interventional study .</brief_summary>
	<brief_title>Comparison Daily Mometasone Furoate Nasal Spray Alone Versus Combination With Montelukast Treatment Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery</brief_title>
	<detailed_description>1 . Surgery plan - Pre-operation : Patients enrol study complete assessment specimen collection first day , follow 1 week drug therapy prednisone ( 30 mg daily ) MFNS ( 200ug , daily ) . - FESS : For patient surgical contraindication , FESS perform . Bilateral nasal cavity fill swell sponge postoperatively . The stuff remove postoperative day 2 . The patient discharge day 3 surgery . - Other treatment : All patient receive nasal irrigation ( normal saline 500 mg twice daily ) postoperative day 3 day 30 . Asthma treat guidance professor Department Respiratory Medicine investigator hospital . 2 . Drug treatment phase Three day surgery ( FESS ) describe , patient assign follow two group ( 30 patient group ) use random number generate statistical software . - Experimental group : Montelukast ( 10mg , daily ) MFNS ( 200μg , daily ) 6 month - Control group : MFNS ( 200μg , daily ) 6 month 3 . Follow After 6-month drug treatment phase , still 3-month follow-up . Totally , 5 visit FESS surgery . - Visit 1 : baseline - Visit 2： Day 31 post-FESS - Visit 3 : Day 61 post-FESS - Visit 4 : Day 91 post-FESS - Visit 5 : Day 181 post-FESS - Visit 6 : Day 271 post-FESS</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Nasal Polyps</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>1 . Diagnosis chronic rhinosinusitis accord European position paper rhinosinusitis nasal polyp 2007 2 . Diagnosis asthma base Global initiative asthma 2012 3 . All patient provide informed consent prior study agree followup appointment . 1 . Immunodeficiency disease , history head and/or facial trauma , cancer organ transplant recipient . 2 . Pregnancy lactation . 3 . Uncontrolled bronchial asthma . 4 . Acute respiratory tract infection within one month study . 5 . Use leukotriene receptor antagonist within 3 month enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>chronic rhinosinusitis</keyword>
	<keyword>asthma</keyword>
	<keyword>montelukast</keyword>
	<keyword>surgery</keyword>
	<keyword>treatment outcome</keyword>
</DOC>